AIRLINK 74.29 Increased By ▲ 0.04 (0.05%)
BOP 5.05 No Change ▼ 0.00 (0%)
CNERGY 4.54 Increased By ▲ 0.12 (2.71%)
DFML 37.47 Increased By ▲ 1.63 (4.55%)
DGKC 91.22 Increased By ▲ 3.22 (3.66%)
FCCL 22.59 Increased By ▲ 0.39 (1.76%)
FFBL 32.78 Increased By ▲ 0.06 (0.18%)
FFL 9.74 Decreased By ▼ -0.05 (-0.51%)
GGL 10.99 Increased By ▲ 0.19 (1.76%)
HBL 115.60 Decreased By ▼ -0.30 (-0.26%)
HUBC 136.40 Increased By ▲ 0.56 (0.41%)
HUMNL 10.17 Increased By ▲ 0.33 (3.35%)
KEL 4.60 Decreased By ▼ -0.01 (-0.22%)
KOSM 5.02 Increased By ▲ 0.36 (7.73%)
MLCF 40.30 Increased By ▲ 0.42 (1.05%)
OGDC 138.35 Increased By ▲ 0.45 (0.33%)
PAEL 27.33 Increased By ▲ 0.90 (3.41%)
PIAA 24.46 Decreased By ▼ -1.82 (-6.93%)
PIBTL 6.73 Decreased By ▼ -0.03 (-0.44%)
PPL 123.50 Increased By ▲ 0.60 (0.49%)
PRL 27.11 Increased By ▲ 0.42 (1.57%)
PTC 14.08 Increased By ▲ 0.08 (0.57%)
SEARL 59.26 Increased By ▲ 0.56 (0.95%)
SNGP 70.00 Decreased By ▼ -0.40 (-0.57%)
SSGC 10.44 Increased By ▲ 0.08 (0.77%)
TELE 8.64 Increased By ▲ 0.08 (0.93%)
TPLP 11.24 Decreased By ▼ -0.14 (-1.23%)
TRG 64.79 Increased By ▲ 0.56 (0.87%)
UNITY 26.61 Increased By ▲ 0.56 (2.15%)
WTL 1.40 Increased By ▲ 0.02 (1.45%)
BR100 7,864 Increased By 25.8 (0.33%)
BR30 25,594 Increased By 134 (0.53%)
KSE100 75,312 Increased By 381 (0.51%)
KSE30 24,200 Increased By 53.9 (0.22%)

imageTOKYO: Japan's top drugmaker Takeda Pharmaceutical has offered $2.2 billion to settle US claims linked to its diabetes drug Actos, in what would be one of the biggest US payouts over patient lawsuits, a report said on Wednesday.

Citing three people familiar with the matter, Bloomberg News said the firm has offered the huge settlement to close more than 8,000 lawsuits alleging it concealed the medicine's cancer risks.

The proposal would amount to a payment of about $275,000 for each case, the report said, adding that a final deal has not yet been reached.

Last year a federal jury in Louisiana ordered Takeda and US-based Eli Lilly & Co. to pay a combined $9.0 billion in damages to a patient who said Actos had caused his bladder cancer. A judge later cut the payout to $36.8 million.

Takeda has faced at least nine trials since 2013 over claims it tried to cover up Actos's cancer risks, including the Louisiana trial.

The company won three cases and some other damage awards have been quashed or are being appealed, Bloomberg said.

But five juries have found the company liable for patients' injuries, it added.

A Tokyo-based spokesman for Takeda declined to discuss the lawsuits or comment on Wednesday's report.

Actos sales peaked in the year ended March 2011 at $4.5 billion and accounted for more than one quarter of Takeda's revenue at the time, according to data compiled by Bloomberg.

Former users accused Takeda executives of ignoring or playing down worries about the drug's cancer links before it went on sale in the US in the late 1990s, and then misleading US regulators about the risks.

Eli Lilly was Takeda's US marketing and sales partner until 2006, with the US firm keeping the rights to sell Actos in parts of Asia and Europe as well as in Canada and Mexico.

Copyright AFP (Agence France-Presse), 2015

Comments

Comments are closed.